Ny styrka Färre tabletter att intas för patienter som behandlas med Braftovi®+Mektovi® BRAFTOVI®’s formulering förblir oförändrad BRAFTOVI® (enkorafenib) i kombination med MEKTOVI® (binimetinib) är indicerat för behandling av vuxna patienter med: icke-resektabelt eller metastaserat melanom med en BRAFV600-mutation1,2 BRAFV600E-muterad…
Det europeiska godkännandet baseras på resultat från fas II-studien PHAROS, som visade klinisk nytta för att BRAFV600E muterade patienter med avancerad NSCLC med en objektiv responsfrekvens (ORR) på 75 procent hos behandlingsnaiva patienter och 46 procent hos tidigare behandlade patienter.1,2,3…
Research summary edited by Pierre Fabre With a median follow-up duration of 100 months, the seven-year analysis from the COLUMBUS trial’s part 1 confirms the long-term, sustained efficacy and known safety profile of encorafenib + binimetinib in patients with BRAFV600-mutant…
In Sweden adjuvant systemic therapies for patients following surgical treatment of high-risk melanoma was introduced as a recommendation in the national guidelines in the end of 2018. Treatment recommendations are based on the AJCC 8th edition staging system, where unfortunately…
In January 2023, Pierre Fabre arranged a national symposium in Gothenburg, Sweden, focusing on the latest insights into the treatment of BRAF-mutant melanoma. The symposium, moderated by Professor Lars Ny, gathered oncologists, surgeons and pathologists involved in diagnosing and treating…
Molecular targeted therapies and immune checkpoint inhibitors have changed the treatment landscape for BRAFV600E-mutant metastatic colorectal cancer (mCRC). This review is based on a scientific literature search and analysis by a European expert panel. It provides consensus statements on management…
The Nordic melanoma meeting was held October 11–13 in Reykjavik and brought together Nordic and international clinicians and researchers. Pierre Fabre’s oncology team was on site and caught up with Professor Roger Olofsson Bagge and Professor Lars Ny to discuss…
The introduction of immune checkpoint inhibitors (ICI) such as the cytotoxic T-lymphocyte-associated antigen 4 inhibitors (CTLA-4) and programmed death 1 inhibitors (PD-1), as well as targeted therapies (TT) exemplified by BRAF and MEK inhibitors have significantly altered the treatment paradigm…
In 2020, approximately 1.9 million people were diagnosed with colorectal cancer (CRC) globally1. At present, survival rates for the metastatic CRC (mCRC) population are poor, with less than 20% of people living for more than five years after diagnosis across…
COLUMBUS-studien: Femårsuppföljning av effekt och säkerhet av BRAF-hämmaren enkorafenib (Braftovi) i kombination med MEK-hämmaren binimetinib (Mektovi) hos patienter med icke-resektabelt eller metastaserat melanom med en BRAF V600-mutation. Abstrakt Fas III COLUMBUS-studien visade att kombinationsbehandling med BRAF-hämmaren enkorafenib och MEK-hämmaren binimetinib…